ATORM

Adult Tissue derived Organoid based Regenerative Medicine

Organoid-based regenerative therapeutics platform

Local transplantation
with scaffolds

Patient

Establishment
of organoids

Biopsy by minimal
invasive methods

Pipeline

Establishment of 4 types of organoid pipelines
Full-scale clinical trials underway for intestinal and salivary gland organoid pipelines

ATORM-C

Intestinal organoid regenerative therapeutic

ATORM-S

Salivary gland organoid regenerative therapeutic

ATORM-E

Endometrium organoid regenerative therapeutic

ATORM-L

Liver organoid regenerative therapeutic

Core Technology

Development of Core Technologies for the Commercialization of Organoid-Based Regenerative Therapies, including Organoid Formulations, GMP-Grade Manufacturing, and Administration Methods

Development of organoid production technology containing high concentrations of stem cells

Our proprietary technology yields intestinal organoids with over four times the stem cell content of native human tissue, significantly enhancing regenerative potential.

Development of delivery method using endoscopy

We developed a user-friendly delivery technique using endoscopy. Therapeutics and fixation materials are injected separately, improving localization while reducing toxicity.

Consistent and optimized organoid culture

ATORM-C Overview

Tissue damage caused by inflammation and radiation leading to serious complications
ATORM-C offers fundamental treatment that induces regeneration of damaged intestinal tissue

Refractory intestinal ulcers that do not respond for over a year even after drug treatment

Mechanism and treatment of intractable intestinal ulcers

Inflammation

Treated with various anti-inflammatory agents

Mucosal damage

No established treatment currently available

ATORM-C Introduction Video

Domestic and global clinical development plans

ATORM-C advanced regenerative medicine clinical research is expected to be commercialized in Korea hospitals in 2027

ATORM-C (Colon Organoids)

Refractory inflammatory bowel diseases (IBD)

Programs (Indications)

Domestic

(Advanced Regenerative Medicine, Chungbuk Regenerative Bio Special Zone)

Collaboration

  • Seoul Asan Medical Center
  • Bundang CHA Hospital
  • Korea University Medical Center
  • Dongguk University Ilsan Hospital
  • Yonsei University

Programs (Indications)

Global Commercialization
(Multinational Phase 2 trial following Korean Phase 1 trial to support BLA in the USA and EU)

Collaboration

  • Mount Sinai NY
  • UKSH (Universitätsklinikum Schleswig-Holstein)
  • Mahidol University
  • UKD (University Hospital Dresden ‘Carl Gustav Carus’)

ATORM-S (Salivary Organoids)

Refractory salivary gland hypofunction

Programs (Indications)

Domestic
(Advanced Regenerative Medicine, Chungbuk Regenerative Bio Special Zone)

Collaboration

  • Konkuk University Medical Center
  • Samsung Medical Center

Toward a Sustainable Future
with ORGANOIDSCIENCES

Join ORGANOIDSCIENCES in leading groundbreaking organoid research and the advancement of next-generation cell therapies.
Be part of the journey of biomedical innovation that is shaping the future of healthcare.

Technical Inquiry

bd@organoidrx.com

PR/Marketing inquiry

pr@organoidrx.com

Recruitment inquiry

hr.admin@organoidrx.com

General Inquiry

info@organoidrx.com